173 related articles for article (PubMed ID: 37703724)
1. Screening for health-related quality of life and its determinants in Fabry disease: A cross-sectional multicenter study.
Winter Y; Hilz M; Beuschlein F; Tsukimura T; Seifritz E; Lenders M; Brand E; Hennermann JB; Nowak A
Mol Genet Metab; 2023 Nov; 140(3):107692. PubMed ID: 37703724
[TBL] [Abstract][Full Text] [Related]
2. De novo Diagnosis of Fabry Disease among Italian Adults with Acute Ischemic Stroke or Transient Ischemic Attack.
Romani I; Borsini W; Nencini P; Morrone A; Ferri L; Frusconi S; Donadio VA; Liguori R; Donati MA; Falconi S; Pracucci G; Inzitari D
J Stroke Cerebrovasc Dis; 2015 Nov; 24(11):2588-95. PubMed ID: 26298600
[TBL] [Abstract][Full Text] [Related]
3. Neurological complications of Anderson-Fabry disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Arnao V; Licata G; Pinto A
Curr Pharm Des; 2013; 19(33):6014-30. PubMed ID: 23448452
[TBL] [Abstract][Full Text] [Related]
4. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
5. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).
Hoffmann B; Garcia de Lorenzo A; Mehta A; Beck M; Widmer U; Ricci R;
J Med Genet; 2005 Mar; 42(3):247-52. PubMed ID: 15744039
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Fabry disease and GLA variants in young patients with acute stroke: The challenge to widen the screening. The Fabry-Stroke Italian Registry.
Romani I; Sarti C; Nencini P; Pracucci G; Zedde M; Cianci V; Nucera A; Moller J; Orsucci D; Toni D; Palumbo P; Casella C; Pinto V; Barbarini L; Bella R; Scoditti U; Ragno M; Mezzapesa DM; Tassi R; Volpi G; Diomedi M; Bigliardi G; Cavallini AM; Chiti A; Ricci S; Cecconi E; Linoli G; Sacco S; Rasura M; Giordano A; Bonetti B; Melis M; Cariddi LP; Dossi RC; Grisendi I; Aguglia U; Di Ruzza MR; Melis M; Sbardella E; Vista M; Valenti R; Musolino RF; Passarella B; Direnzo V; Pennisi G; Genovese A; Di Marzio F; Sgobio R; Acampa M; Nannucci S; Dagostino F; Dell'Acqua ML; Cuzzoni MG; Picchioni A; Calchetti B; Notturno F; Di Lisi F; Forlivesi S; Delodovici ML; Buechner SC; Biagini S; Accavone D; Manna R; Morrone A; Inzitari D
J Neurol Sci; 2024 Feb; 457():122905. PubMed ID: 38295534
[TBL] [Abstract][Full Text] [Related]
7. The impact of demographic and clinical characteristics on the trajectories of health-related quality of life among patients with Fabry disease.
Sigurdardottir S; Bjerkely B; Jenssen TG; Mathisen P; von der Lippe C; Ørstavik K; Heimdal K; Dahle DO; Weedon-Fekjær MS; Solberg O; Pihlstrøm HK
Orphanet J Rare Dis; 2021 Oct; 16(1):427. PubMed ID: 34641933
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease: Review and experience during newborn screening.
Hsu TR; Niu DM
Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
[TBL] [Abstract][Full Text] [Related]
9. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
10. First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland.
Nowicki M; Komar M; Kusztal M; Mizia-Stec K; Liberek T; Małyszko J; Muras-Szwedziak K; Pawlaczyk K; Podolec P; Sławek J
F1000Res; 2021; 10():841. PubMed ID: 34745562
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Fabry Disease in Young Patients with Stroke in Argentina.
Reisin RC; Mazziotti J; Cejas LL; Zinnerman A; Bonardo P; Pardal MF; Martínez A; Riccio P; Ameriso S; Bendersky E; Nofal P; Cairola P; Jure L; Sotelo A; Rozenfeld P; Ceci R; Casas-Parera I; Sánchez-Luceros A;
J Stroke Cerebrovasc Dis; 2018 Mar; 27(3):575-582. PubMed ID: 29132836
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported experience with Fabry disease and its management in the real-world setting: results from a double-blind, cross-sectional survey of 280 respondents.
Berry L; Walter J; Johnson J; Alton J; Powers J; Llòria X; Koulinska I; McGee M; Laney D
Orphanet J Rare Dis; 2024 Apr; 19(1):153. PubMed ID: 38605390
[TBL] [Abstract][Full Text] [Related]
13. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study.
Arends M; Körver S; Hughes DA; Mehta A; Hollak CEM; Biegstraaten M
J Inherit Metab Dis; 2018 Jan; 41(1):141-149. PubMed ID: 29039131
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort.
Nowak A; Huynh-Do U; Krayenbuehl PA; Beuschlein F; Schiffmann R; Barbey F
J Inherit Metab Dis; 2020 Mar; 43(2):326-333. PubMed ID: 31449323
[TBL] [Abstract][Full Text] [Related]
15. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease in unselected patients with TIA or stroke: population-based study.
Marquardt L; Baker R; Segal H; Burgess AI; Poole D; Hughes DA; Rothwell PM
Eur J Neurol; 2012 Nov; 19(11):1427-32. PubMed ID: 22537551
[TBL] [Abstract][Full Text] [Related]
17. Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.
Lenders M; Weidemann F; Kurschat C; Canaan-Kühl S; Duning T; Stypmann J; Schmitz B; Reiermann S; Krämer J; Blaschke D; Wanner C; Brand SM; Brand E
Orphanet J Rare Dis; 2016 May; 11(1):54. PubMed ID: 27142856
[TBL] [Abstract][Full Text] [Related]
18. The heart in Fabry's disease.
Sheppard MN
Cardiovasc Pathol; 2011; 20(1):8-14. PubMed ID: 19919901
[TBL] [Abstract][Full Text] [Related]
19. Nationwide screening for Fabry disease in unselected stroke patients.
Tomek A; Petra R; Paulasová Schwabová J; Olšerová A; Škorňa M; Nevšímalová M; Šimůnek L; Herzig R; Fafejtová Š; Mikulenka P; Táboříková A; Neumann J; Brzezny R; Sobolová H; Bartoník J; Václavík D; Vachová M; Bechyně K; Havlíková H; Prax T; Šaňák D; Černíková I; Ondečková I; Procházka P; Rajner J; Škoda M; Novák J; Škoda O; Bar M; Mikulík R; Dostálová G; Linhart A;
PLoS One; 2021; 16(12):e0260601. PubMed ID: 34905550
[TBL] [Abstract][Full Text] [Related]
20. Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.
Suntjens EB; Smid BE; Biegstraaten M; Dreschler WA; Hollak CE; Linthorst GE
J Inherit Metab Dis; 2015 Mar; 38(2):351-8. PubMed ID: 25395255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
